Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Boston, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Spectrum Pharmaceuticals, Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Spectrum Pharmaceuticals, Inc. market cap is $211.4M.
What is the 52-week high for Spectrum Pharmaceuticals, Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Spectrum Pharmaceuticals, Inc. 52 week high is $1.57 as of September 05, 2025.
What is the 52-week low for Spectrum Pharmaceuticals, Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Spectrum Pharmaceuticals, Inc. 52 week low is $0.315 as of September 05, 2025.
What is Spectrum Pharmaceuticals, Inc. stock price today?
Spectrum Pharmaceuticals, Inc. stock price today is $1.03.
What was Spectrum Pharmaceuticals, Inc. stock price yesterday?
Spectrum Pharmaceuticals, Inc. stock price yesterday was $1.03.
What is the PE ratio of Spectrum Pharmaceuticals, Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Spectrum Pharmaceuticals, Inc.’s P/E ratio is -2.93.
What is the Price-to-Book ratio of Spectrum Pharmaceuticals, Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Spectrum Pharmaceuticals, Inc. P/B ratio is 7.8885.
What is Spectrum Pharmaceuticals, Inc.'s EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Spectrum Pharmaceuticals, Inc.'s EBITDA is -2.01.
What is the 50-day moving average of Spectrum Pharmaceuticals, Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Spectrum Pharmaceuticals, Inc. 50-day moving average is $1.03.
